A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)
Clinical trial NCT05722015 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05722015
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-02-14
- Primary completion
- 2024-07-12
- Enrollment
- 377
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.